Daniel Ricketti, MD
Cardiovascular Disease · Chillicothe, OHNPI 1538653548
Payments from drug & device makers
What this record shows
This record is dominated by grants: $14,000 of the $17,597 with a category attached, or 79.6%. 11 manufacturers reported payments, led by Boston Scientific at 46.1% of the total. 2025 is the largest year on record at $17,171, more than ten times the $258 reported in 2022.
Across 30 payments — averaging $586.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$8K
- Medtronic$5K
- Abbott$4K
- Actelion Pharmaceuticals US, Inc.$129
- Kestra Medical Technology Services, Inc.$123
- Atricure, Inc.$118
- plus $120 from 5 others
What the payments were for
- Grants$14,00080%
- Travel & lodging$1,3548%
- Food & beverage$2,24313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $8,108 |
| Medtronic | 1 | $5,000 |
| Abbott | 2 | $4,000 |
| Actelion Pharmaceuticals US, Inc. | 1 | $129 |
| Kestra Medical Technology Services, Inc. | 1 | $123 |
| Atricure, Inc. | 1 | $118 |
| Cordis US CORP. | 1 | $34 |
| Biosense Webster, Inc. | 2 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $23 |
| Chiesi USA, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM MRI S-ICD$5,000
- GENERAL - THERAPIES$2,846
- ASSURITY$2,000
- TACTICATH$2,000
- UPTRAVI$129
- OPSUMIT$129
- Assure WCD$123
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$118
How this compares
$17,597 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $9,754 |
| Rosuvastatin Calcium | 20 | $378 |
| Metoprolol Succinate | 22 | $112 |
| ClopidogrelClopidogrel Bisulfate | 13 | $77 |
| Carvedilol | 13 | $48 |
| Amlodipine Besylate | 20 | $42 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chillicothe
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
- Jayanta MukherjeeColumbus$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.